Evidence map›Paper›PMID 32258140›Full record

Trial reportBioMed research international2020

Dosimetric Comparison of Three Radiotherapy Techniques in Irradiation of Left-Sided Breast Cancer Patients after Radical Mastectomy.

Jian Hu, Guang Han, Yu Lei, Ximing Xu, Wei Ge, Changli Ruan, Sheng Chang, Aihua Zhang, Xiangpan Li

Abstract readCase ReportsClinical TrialComparative Study
In one paragraph

Trial report in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jian HuDepartment of Radiation Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.
Guang HanDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079 Hubei Province, China.ORCID https://orcid.org/0000-0001-5500-3338
Yu LeiDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, USA.ORCID https://orcid.org/0000-0002-8067-3015
Ximing XuDepartment of Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.
Wei GeDepartment of Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.
Changli RuanDepartment of Radiation Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.
Sheng ChangDepartment of Radiation Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.
Aihua ZhangDepartment of Radiation Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.
Xiangpan LiDepartment of Radiation Oncology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

resultsThe VMAT plans showed superior to PTV dose conformity index (CI), homogeneity index (HI), protection of the ipsilateral lung, monitor units (MUs), and maximum dose (D

conclusionsOur study indicates that VMAT should be a better choice of radiotherapy for left-sided breast cancer patients after radical mastectomy. If VMAT is unavailable, 9FIMRT can achieve better CI and HI values and be more MU-efficient compared with TSP; however, TSP can effectively reduce the low dose volume of the ipsilateral lungs and heart.

Indexed as

Mastectomy, RadicalRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedUnilateral Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedRadiotherapy Dosage

Identifiers

PMID32258140
PMCPMC7085359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.